WO2018226178A3 - (e)-1-(4-cinnamoyl-phenyl)-1 h-pyrrole-2,5-dione derivatives having anti-cancerogenic efficiency - Google Patents

(e)-1-(4-cinnamoyl-phenyl)-1 h-pyrrole-2,5-dione derivatives having anti-cancerogenic efficiency Download PDF

Info

Publication number
WO2018226178A3
WO2018226178A3 PCT/TR2017/050521 TR2017050521W WO2018226178A3 WO 2018226178 A3 WO2018226178 A3 WO 2018226178A3 TR 2017050521 W TR2017050521 W TR 2017050521W WO 2018226178 A3 WO2018226178 A3 WO 2018226178A3
Authority
WO
WIPO (PCT)
Prior art keywords
cinnamoyl
pyrrole
phenyl
cancerogenic
efficiency
Prior art date
Application number
PCT/TR2017/050521
Other languages
French (fr)
Other versions
WO2018226178A2 (en
Inventor
Yakup Budak
Mustafa Ceylan
M. Burcu GURDERE
Original Assignee
Yakup Budak
Mustafa Ceylan
Gurdere M Burcu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakup Budak, Mustafa Ceylan, Gurdere M Burcu filed Critical Yakup Budak
Publication of WO2018226178A2 publication Critical patent/WO2018226178A2/en
Publication of WO2018226178A3 publication Critical patent/WO2018226178A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to (E)-1 -(4-cinnamoyl-phenyl)-1 H-pyrrole-2,5-dione derivatives shown by Formula (1), the preparation methods of these molecules, the formulations comprising these molecules and the usage of these molecules in treatment of cancer.
PCT/TR2017/050521 2016-10-26 2017-10-25 (e)-1-(4-cinnamoyl-phenyl)-1 h-pyrrole-2,5-dione derivatives having anti-cancerogenic efficiency WO2018226178A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2016/15186A TR201615186A2 (en) 2016-10-26 2016-10-26 (E) -1- (4-CINNAMOYLPHENYL) -1H-PYROL-2,5-DIONE DERIVATIVES WITH ANTICANSEROGEN ACTIVITY
TR2016/15186 2016-10-26

Publications (2)

Publication Number Publication Date
WO2018226178A2 WO2018226178A2 (en) 2018-12-13
WO2018226178A3 true WO2018226178A3 (en) 2019-03-14

Family

ID=64567447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050521 WO2018226178A2 (en) 2016-10-26 2017-10-25 (e)-1-(4-cinnamoyl-phenyl)-1 h-pyrrole-2,5-dione derivatives having anti-cancerogenic efficiency

Country Status (2)

Country Link
TR (1) TR201615186A2 (en)
WO (1) WO2018226178A2 (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIRUDUKOTA, N.: "escape from flatland :chemo-enzymatic synthesis and biological profiling of a library of bridged bicyclic compounds", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 14, 22 March 2016 (2016-03-22), pages 3821 - 3837, XP055580986, ISSN: 1477-0520, DOI: 10.1039/C5OB02539G *
CEYLAN, M.: "Synthesis, characterization and biological activities of novel chalcone derivatives, containing 4, 7-ethanoisoindole-1, 3-dione units", ACG PUBLICATIONS- ORGANIC COMMUNICATIONS, vol. 6, no. 3, 25 September 2013 (2013-09-25) - 26 June 2013 (2013-06-26), pages 102 - 109, XP055580990, ISSN: 1307-6175 *
MUKHERJEE, C.ET AL.: "Cytostatic activity of novel 4'-aminochalcone-based imides", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 7 June 2007 (2007-06-07) - 17 July 2007 (2007-07-17), pages 4545 - 4550, XP022156486 *

Also Published As

Publication number Publication date
WO2018226178A2 (en) 2018-12-13
TR201615186A2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
CY1121517T1 (en) NON-FUCUCYLIZED ANTIBODIES ENANTI-FGFR2IIIB
EA201991503A1 (en) PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
MX2016002544A (en) Compounds useful as immunomodulators.
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
MX2016013689A (en) 4-amino-imidazoquinoline compounds.
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
EA201890754A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
EA201590997A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
EA201691913A1 (en) SUBSTITUTED [1,2,4] TRIAZOL AND IMIDAZOL COMPOUNDS AS FUNGICIDES
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
EA201692526A1 (en) SUBSTITUTED [1,2,4] TRIAZOLE COMPOUNDS
EA201170252A1 (en) AMIDOPHENOXINDAZOLES AS C-MET INHIBITORS
CY1123490T1 (en) COMPOSITIONS DERIVED FROM CHITOZAN
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2010003365A (en) Thiazol derivatives for treating cancer.
AU2015352440B2 (en) Compounds
EA033460B1 (en) Substituted [1,2,4]triazole compounds as fungicides
EA201070281A1 (en) INDOL-2-ONE DERIVATIVES, DOUBLE SUBSTITUTES IN POSITION 3, THEIR RECEIVING AND THEIR USE IN THERAPY

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17912685

Country of ref document: EP

Kind code of ref document: A2